AstraZeneca partners with AI company to find cure for cancer
The collaboration aims to create a zero-shot generative AI model, which would work on creating new antibody therapeutics and enhancing the existing ones.
The pharmaceutical company that developed one of the vaccines for COVID-19, AstraZeneca, will partner with a United States-based Artificial Intelligence (AI) biologics firm, Absci, to design an antibody for cancer.
According to a Financial Times report on Dec.
Related: AI in healthcare. New tech in diagnosis and patient care
Absci’s website claims its AI screens “billions of cells” each week, going from antibodies to wet “lab-validated candidates” in six weeks.
“AI is enabling us to not only increase the success and speed of our biologics discovery process, but also enhance the diversity of the biologics we discover.”
Absci CEO Sean McClain had also publicly confirmed the partnership, stating that AstraZeneca will help to leverage its AI work, according to a Reuters report.
AI is gaining momentum in the healthcare industry, as it could significantly accelerate both innovative research and the accuracy of data analysis. In November, Hong Kong’s Hospital Authority revealed the launch of an AI pilot to combat multidrug-resistant organisms or superbugs.
